Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides)

2020 ◽  
Author(s):  
Alessandro Pileri ◽  
Alba Guglielmo ◽  
Annalisa Patrizi ◽  
Beatrice Casadei ◽  
Clara Bertuzzi ◽  
...  
Keyword(s):  
Side Effects ◽  
Mycosis Fungoides ◽  
Brentuximab Vedotin ◽  
Skin Side Effects

New therapies and old side‐effects in mycosis fungoides treatment: brentuximab vedotin‐induced alopecia

2019 ◽  
Vol 180 (6) ◽  
pp. 1535-1536 ◽  
Author(s):  
A. Pileri ◽  
M. Starace ◽  
A. Alessandrini ◽  
B. Casadei ◽  
P.L. Zinzani ◽  
...  
Keyword(s):  
Side Effects ◽  
Mycosis Fungoides ◽  
Brentuximab Vedotin ◽  
New Therapies

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview

2019 ◽  
Vol 14 (1) ◽  
pp. 14-20 ◽  
Author(s):  
Kerasia-Maria Plachouri ◽  
Eleftheria Vryzaki ◽  
Sophia Georgiou
Keyword(s):  
Side Effects ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Skin Toxicity ◽  
Maculopapular Rash ◽  
Symptomatic Treatment ◽  
Stevens Johnson Syndrome ◽  
Life Threatening ◽  
Skin Side Effects

Background:The introduction of Immune Checkpoint Inhibitors in the recent years has resulted in high response rates and extended survival in patients with metastatic/advanced malignancies. Their mechanism of action is the indirect activation of cytotoxic T-cells through the blockade of inhibitory receptors of immunomodulatory pathways, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and its ligand (PD-L1). Despite their impressive therapeutic results, they can also induce immune-related toxicity, affecting various organs, including the skin.Objective:To provide an updated summarized overview of the most common immune-mediated cutaneous side effects and their management.Method:English articles derived from the databases PubMed and SCOPUS and published between 2009 and 2018, were analyzed for this narrative review.Results:The most common adverse cutaneous reactions include maculopapular rash, lichenoid reactions, vitiligo and pruritus, with severity Grade 1 or 2. Less frequent but eventually life-threatening skin side effects, including Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Toxic Epidermal necrolysis, have also been reported.Conclusion:Basic knowledge of the Immune-Checkpoint-Inhibitors-induced skin toxicity is necessary in order to recognize these treatment-related complications. The most frequent skin side effects, such as maculopapular rash, vitiligo and pruritus, tend to subside under symptomatic treatment so that permanent discontinuation of therapy is not commonly necessary. In the case of life-threatening side effects, apart from the necessary symptomatic treatment, the immunotherapy should be permanently stopped. Information concerning the management of ICIs-mediated skin toxicity can be obtained from the literature as well as from the Summary of Product Characteristics of each agent.

Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides)

2021 ◽  
Vol 19 (1) ◽  
pp. 99-102
Author(s):  
Alessandro Pileri ◽  
Alba Guglielmo ◽  
Annalisa Patrizi ◽  
Beatrice Casadei ◽  
Clara Bertuzzi ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Brentuximab Vedotin

scholarly journals Skin Side Effects of Inflammatory Bowel Disease Therapy

2013 ◽  
Vol 19 (5) ◽  
pp. 1086-1098 ◽  
Author(s):  
Joana Torres ◽  
Sébastien Buche ◽  
Emmanuel Delaporte ◽  
Jean-Frédéric Colombel
Keyword(s):  
Inflammatory Bowel Disease ◽  
Side Effects ◽  
Bowel Disease ◽  
Disease Therapy ◽  
Inflammatory Bowel ◽  
Skin Side Effects

Skin Side Effects Due To Vortioxetine Case Series

2021 ◽  
Vol 11 (4) ◽  
pp. 284
Author(s):  
Mehmet Gunes ◽  
Ezgi Inan
Keyword(s):  
Side Effects ◽  
Case Series ◽  
Skin Side Effects

Guttate psoriasis in a patient with Mycosis Fungoides in treatment with Brentuximab vedotin: an unreported association

2022 ◽  
Author(s):  
Gabriele Roccuzzo ◽  
Francesco Cavallo ◽  
Gianluca Avallone ◽  
Paolo Fava ◽  
Luca Conti ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Brentuximab Vedotin ◽  
Guttate Psoriasis

Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin

2019 ◽  
Vol 33 (1) ◽  
Author(s):  
Svetlana Popadic ◽  
Branislav Lekic ◽  
Srdjan Tanasilovic ◽  
Martina Bosic ◽  
Milos Nikolic
Keyword(s):  
Mycosis Fungoides ◽  
Cell Transformation ◽  
Large Cell ◽  
Brentuximab Vedotin ◽  
Large Cell Transformation

Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration

2020 ◽  
pp. 107815522097062
Author(s):  
Uğur Çelik ◽  
Ertuğrul H Aydemir ◽  
Burhan Engin ◽  
Muazzez Ç Oba ◽  
Mesut Yılmaz ◽  
...  
Keyword(s):  
Side Effects ◽  
Outpatient Clinic ◽  
Targeted Therapies ◽  
Side Effect ◽  
Common Side Effect ◽  
Cancer Therapies ◽  
Anti Cancer ◽  
Targeted Cancer Therapies ◽  
Dermatological Side Effects ◽  
Skin Side Effects

Introduction Novel anti-cancer drugs such as targeted cancer therapies and immune check-point inhibitors (ICIs) have adverse events, especially concerning the skin. The aim of this study is to report an overview of the commonly consulted dermatological side effects of ICIs and targeted cancer therapies in clinical practice, along with their management. Methods In this single-center study, we evaluated consecutive oncological patients who were referred from the oncology outpatient clinic to the dermatology outpatient clinic due to skin side effects of ICIs and targeted therapies. All patients were examined and treated at the same day of referral by experienced dermatologists. Patient characteristics, clinical findings, diagnostic workups and treatments were retrieved from outpatient records. Results Sixty three patients were enrolled. Most common diagnoses were lung carcinoma, melanoma and colon carcinoma. Fifty patients (79%) were using targeted therapies while 13 (21%) were using ICIs. Xerosis was the most common side effect (44%), followed by acneiform rash, paronychia, eczema and pruritus. Majority of the side effects were grade 2 and 3. Psoriasis was a common side effect of ICIs. One patient had a newly developed dysplastic nevus on vemurafenib treatment. Oncological treatment was not withheld in any of the patients. Conclusions This study revealed the most commonly consulted skin side effects of novel anti-cancer drugs and their management in daily practice. We underlie the importance of collaborative work of oncology and dermatology professionals as early management of cutaneous side effects of targeted therapies and ICIs improves patient outcomes.

Sign in / Sign up

Export Citation Format

Share Document